About Arkis BioSciences
Arkis BioSciences is a company based in Knoxville (United States) founded in 2011 was acquired by Integra LifeSciences in July 2019. Arkis BioSciences has raised $9.38 million across 3 funding rounds from investors including Integra LifeSciences, Innova Memphis and The Lighthouse Fund. Arkis BioSciences operates in a competitive market with competitors including Rapid Medical, CoAxia, Cerus Endovascular, Anaconda Biomed and Oxford Endovascular, among others.
- Headquarter Knoxville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.38 M (USD)
in 3 rounds
-
Latest Funding Round
$4.48 M (USD), Series A
Jan 11, 2018
-
Investors
Integra LifeSciences
& 3 more
-
Employee Count
Not available
-
Acquired by
Integra LifeSciences
(Jul 29, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Arkis BioSciences
Arkis BioSciences has successfully raised a total of $9.38M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.48 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arkis BioSciences
Arkis BioSciences has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Integra LifeSciences, Innova Memphis and The Lighthouse Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in high-growth technology companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Arkis BioSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arkis BioSciences
Investment portfolio details for Arkis BioSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arkis BioSciences
Detailed financials for Arkis BioSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arkis Biosciences Comparisons
Peer comparison for Arkis BioSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arkis BioSciences
Arkis BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rapid Medical, CoAxia, Cerus Endovascular, Anaconda Biomed and Oxford Endovascular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurovascular interventional devices including distal access catheters are developed.
|
|
| Locked | Locked | Locked |
Catheter-based treatment for cerebral ischemia
|
|
| Locked | Locked | Locked |
Interventional neuroradiology devices are developed for minimally invasive aneurysm treatment.
|
|
| Locked | Locked | Locked |
Medical devices for mechanical thromboectomy and clot removal are developed.
|
|
| Locked | Locked | Locked |
Metallic mesh devices for brain aneurysms are developed.
|
|
| Locked | Locked | Locked |
A hybrid polymer-metal stent for brain aneurysms is developed.
|
Detailed competitors of Arkis BioSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arkis Biosciences
Complete news archive for Arkis BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arkis BioSciences
Arkis BioSciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Arkis BioSciences is headquartered in Knoxville, United States. It is registered at Knoxville, Tennessee, United States.
Arkis BioSciences is a funded company, having raised a total of $9.38M across 3 funding rounds to date.
Arkis BioSciences develops technology for the neurosurgical treatments for intracranial hypertension arising from hydrocephalus, traumatic brain injury, hemorrhagic stroke and similar disorders. Their product offering includes Tunneling Guidewire Kit - shunt passer that combines a tunneling instrument with the precision of guidewire steering; Endexo molecule - a self-locating fluoro-oligomeric polymer that results in a passivated surface, thereby reducing protein adsorption, platelet adhesion and activation, and thrombus formation in catheter lumens.
Arkis BioSciences's top competitors include Rapid Medical, Fluid Biomed and Anaconda Biomed.
Arkis BioSciences has 4 investors. Key investors include Integra LifeSciences, Innova Memphis, The Lighthouse Fund, and Angel Capital Group.